Big Pharma Injures Healthy Women with Yaz Side Effects

Studies performed on healthy, premenopausal women in the Netherlands established that Yaz, Yasmin, and Ocella (Yasmin generic) suffered an enhanced risk of venous thrombosis as compared to non-users. The risks were increased as high as five times with oral contraceptive pills. These reports were published in August 2009. This was only the beginning of the contention surrounding Yaz, Yasmin, and Ocella and the consequent lawsuits to come regarding Yaz side effects.

Mass Tort is simply civil action that embodies a number of complainants. This process is taken against one or more corporate litigants in court. Unlike a class action where a number of people take it upon themselves to bring forth litigation as a whole, in mass tort the original plaintiffs and law firms use mass media resources to reach other possible plaintiffs that they would not ordinarily meet. Those TV ads and newspaper solicitations wondering if you are a loved one have been effected by a particular product are the result of mass tort status.

It is fundamental that women become their own advocates and take charge of the decisions being made about their health and their bodies. As a whole, the American public relies too heavily on doctors and pharmaceuticals to give them answers in a bottle. In the internet age, it is up to you to do your own research and remain knowledgeable. Drug recalls and corporate lawsuits have become all too commonplace in America. At some point, the masses have to stop looking to the government and big business to have their wellbeing in mind. It is time for the public to at long last take the first step and not be so quick to accept anything handed to them in pill form.

Enjoyed this post? Tell your friends! These icons link to social bookmarking sites where readers can share and discover new web pages.
  • OnlyWire
  • Socialize-It
  • bodytext
  • del.icio.us
  • Furl
  • StumbleUpon
  • Propeller
  • YahooMyWeb
  • Reddit
  • Slashdot
  • Ma.gnolia
  • RawSugar

Comments are closed.